Management Team
Duke Street Bio has an experienced and proven management team with an exceptional track record of delivering clinical molecules across therapeutic areas.

Peter Trill
Chairman

Dr Alan Wise
Chief Executive Officer

Dr Phill Cowley
Chief Scientific Officer
Scientific Advisors
Duke Street Bio draws on the expertise and experience of its Scientific Advisory Board comprised of an extensive network of internationally-renowned scientists, physicians and key opinion leaders

Prof Timothy Yap
Medical Director,
Institute for Applied Cancer Science,
University of Texas
MD Anderson Cancer Center

Dr Elena Garralda
Director, Early Drug Development, Vall d’Hebron Institute of Oncology, Barcelona

Dr Christopher Hill
former Vice President,
Head of Global Chemistry, MSD

Dr Phill L’Huillier
CEO Scancell Ltd, formerly CEO CatalYm GmbHl

Prof Nicola Curtin
Professor of Experimental Cancer Therapeutics,
Newcastle University

Prof Christina Yap
Prof of Clinical Trials Biostatistics, Institute of Cancer Research, London

Dr Elliott Sigal
Senior Advisor, New Enterprise Associates; Co-Chair SAB, Amgen; former CSO, Bristol Myers Squibb

Dr Jennifer Guerriero
Dana-Farber/Harvard Cancer Center,
Brigham and Women’s Hospital,
Harvard Medical School

Dr Emiliano Calvo Aller
Director Clinical Resaerch, STARTMadrid

Prof Anthony Chalmers
Professor of Clinical Oncology, University of Glasgow

Dr Rebecca Kristeleit
Guy’s and St Thomas’ NHS Foundation Trust, King’s College London

Dr Rob Williams
Chief Drug Development
Scientist, CRUK

Dr Ronan O'Hagan
CSO, Apricity Health;
former Executive Director, Oncology Discovery, MSD

Dr Stefan Symeonides
CRUK Edinburgh Centre,
MRC Institute of Genetics & Molecular Medicine,
University of Edinburgh

Prof Johann De Bono
Head of Division of Clinical Studies, Institute for Cancer Research, London

Delivering life-saving cancer treatments to improve patient outcomes.